Journal article icon

Journal article

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV

Abstract:

Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial (NCT04400838), 54 HIV positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and MesoScale Discovery (MSD)), neutralisation,...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1172/jci.insight.157031

Authors


Expand authors...
Publisher:
American Society for Clinical Investigation Publisher's website
Journal:
JCI Insight Journal website
Volume:
7
Issue:
7
Article number:
e157031
Place of publication:
United States
Publication date:
2022-02-22
Acceptance date:
2022-02-18
DOI:
EISSN:
2379-3708
Pmid:
35192543
Language:
English
Keywords:
Pubs id:
1240641
Local pid:
pubs:1240641
Deposit date:
2022-03-15

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP